<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of drug-resistant genital herpes simplex virus infection in patients with HIV
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of drug-resistant genital herpes simplex virus infection in patients with HIV
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of drug-resistant genital herpes simplex virus infection in patients with HIV
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christine Johnston, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna Wald, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 01, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H28740777">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genital herpes simplex is a common sexually transmitted viral infection that is found worldwide [
         <a href="#rid1">
          1
         </a>
         ]. Most often genital herpes is secondary to herpes simplex virus type 2 (HSV-2), although HSV type 1 (HSV-1) has become more common than HSV-2 in high-income countries [
         <a href="#rid1">
          1
         </a>
         ]. Drug resistance to
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         and related drugs (eg,
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         ) is rare in immunocompetent hosts but is seen more commonly among immunocompromised hosts, including patients with HIV and transplant recipients.
        </p>
        <p>
         This topic will review therapeutic options and strategies for prevention of drug-resistant infection in the patient with HIV. The epidemiology, natural history, clinical manifestations, and treatment of drug-sensitive HSV infection in the patient with HIV are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16254.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16255.html" rel="external">
          "Treatment of genital herpes simplex virus type 2 in people living with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28740792">
         <span class="h1">
          MECHANISMS OF DRUG RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         , and
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         are antiviral agents within the nucleoside analog class. After intracellular uptake, acyclovir is converted to acyclovir monophosphate by virally-encoded thymidine kinase [
         <a href="#rid2">
          2
         </a>
         ]. The monophosphate derivative is subsequently converted by cellular enzymes to acyclovir triphosphate, which is a specific inhibitor of HSV DNA polymerase. HSV drug resistance to acyclovir confers broad cross-resistance to this entire class of antiviral agents. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview", section on 'Mechanism of action'
         </a>
         .)
        </p>
        <p>
         Three mechanisms have been found that result in resistance to
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         [
         <a href="#rid3">
          3,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced or absent thymidine kinase
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Altered thymidine kinase activity resulting in decreased
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         phosphorylation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Altered viral DNA polymerase with decreased affinity for
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         triphosphate
        </p>
        <p>
        </p>
        <p>
         Analysis of isolates from a series of 12 AIDS patients with resistant HSV-2 indicated marked thymidine kinase deficiency in each case; these strains were cross-resistant to
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         , which also requires phosphorylation for antiviral activity, but were sensitive to
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         , which acts by directly inhibiting DNA polymerase [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="local">
          'Management of drug-resistant ulcerative disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H28740799">
         <span class="h1">
          PREVALENCE OF DRUG RESISTANCE
         </span>
        </p>
        <p class="headingAnchor" id="H1908854">
         <span class="h2">
          Epidemiologic studies of drug resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         drug resistance is rare among immunocompetent persons; epidemiologic surveys have documented acyclovir-resistant virus in less than 1 percent of immunocompetent individuals [
         <a href="#rid6">
          6,7
         </a>
         ]. Acyclovir drug resistance is more prevalent among immunocompromised patients, including those with HIV [
         <a href="#rid8">
          8-11
         </a>
         ]. In a study of 3602 patients seen in sexually transmitted disease (STD) clinics with genital ulcerative disease, 2088 had evidence of HSV-2 infection [
         <a href="#rid9">
          9
         </a>
         ]. Laboratory testing demonstrated that 3 of 1644 (0.18 percent) HIV-seronegative patients had evidence of HSV-2 drug resistance compared with 12 of 226 (5.3 percent) HIV-seropositive patients.
        </p>
        <p class="headingAnchor" id="H1908861">
         <span class="h2">
          Clinical importance of drug resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical importance of these laboratory findings is unclear since documentation of HSV-resistant strains from herpetic lesions does not necessarily predict failure of
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         therapy [
         <a href="#rid4">
          4,12
         </a>
         ]. Most acyclovir-resistant viruses are TK-deficient strains, which appear less virulent in vitro than acyclovir-sensitive HSV. In addition, no person-to-person transmission of TK-deficient HSV stains has been documented [
         <a href="#rid13">
          13
         </a>
         ]. Rare reports of clinically important drug-resistant HSV disease have been documented in the immunocompetent host [
         <a href="#rid14">
          14
         </a>
         ]; however, among normal hosts, TK-deficient strains usually spontaneously clear without treatment [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Clinically significant drug resistance to
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         has been infrequently reported in immunocompromised individuals. As an example, in one retrospective study from a single clinic in France, only 13 of 5295 (0.2 percent) patients with HIV were diagnosed with acyclovir-resistant HSV infection [
         <a href="#rid15">
          15
         </a>
         ]. Some experts suggest that the risk of drug resistance is higher in these patients because antiviral drug exposure is often prolonged due to slower healing and higher amounts of virus, increasing the risk of resistant mutants [
         <a href="#rid13">
          13
         </a>
         ]. Thus, the laboratory confirmation of acyclovir drug resistance is an important finding in a patient who has persistent or expanding HSV-related lesions, despite adequate antiviral therapy. Such a finding would support the need for alternative treatment, which is discussed below. (See
         <a class="local">
          'Management of drug-resistant ulcerative disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1909852">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with HIV, risk factors for HSV drug resistance include a history of recurrent HSV infection, prior
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         exposure (particularly if the patient was treated with a suboptimal dose), history of a non-healing lesion, and low CD4 cell counts [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H28740813">
         <span class="h1">
          WHEN TO SUSPECT HSV-RELATED DRUG RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug-resistant infection should be suspected among patients with documented HSV who have minimal improvement, or an increase in lesion size, within 7 to 10 days of appropriately dosed antiviral therapy [
         <a href="#rid18">
          18,19
         </a>
         ]. The dose and duration of antiviral therapy used to treat genital HSV infection in patients with HIV differs compared to those without HIV and is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16255.html" rel="external">
          "Treatment of genital herpes simplex virus type 2 in people living with HIV", section on 'Dosing guidelines for antiviral therapy'
         </a>
         .)
        </p>
        <p>
         Unusual presentations of mucocutaneous HSV infection are more common in severely immunocompromised patients, such as patients with AIDS or bone marrow transplant recipients. However, atypical manifestations of HSV infection do not necessarily imply
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         drug resistance. (See
         <a class="medical medical_review" href="/z/d/html/16254.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in patients with HIV", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28740820">
         <span class="h1">
          DIAGNOSIS OF DRUG RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug resistance testing should only be performed in patients with clinical treatment failure in response to nucleoside analog therapy [
         <a href="#rid20">
          20,21
         </a>
         ]. Routine baseline testing of all patients for
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         drug resistance is not recommended.
        </p>
        <p>
         Phenotypic testing of viral isolates is used for assessing HSV resistance [
         <a href="#rid19">
          19
         </a>
         ]. The most widely recommended test is the plaque reduction assay: an IC50 ≥2 mcg/mL indicates that phenotypic resistance is present. A correlation has been established between in vitro
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         susceptibility and clinical response [
         <a href="#rid4">
          4,22
         </a>
         ].
        </p>
        <p>
         To perform phenotypic testing, an isolate from culture is needed; thus, a sample for viral culture must be obtained. Our institution sends samples to LabCorp (1-800-598-3345) for the "HSV 1/2 phenotyping for
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         drug resistance" test using a plaque reduction assay. Downsides of this assay include a long turn-around time (ie, 15 to 17 days). If there is any question regarding the underlying diagnosis, an additional sample can be obtained for polymerase chain reaction (PCR) testing, which is more sensitive than culture for documenting HSV infection. (See
         <a class="medical medical_review" href="/z/d/html/8347.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Ninety-five percent of acyclovir-resistant strains have mutations in the viral thymidine kinase gene; the remaining 5 percent of
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         resistance is due to mutations in the viral DNA polymerase gene [
         <a href="#rid23">
          23
         </a>
         ]. Sequencing of these genes for genotypic diagnosis of acyclovir resistance is available for clinical use from at least one laboratory in the United States [
         <a href="#rid24">
          24
         </a>
         ]. With increasing identification of thymidine kinase polymorphisms and mutants associated with acyclovir drug resistance [
         <a href="#rid23">
          23,25
         </a>
         ], there is hope that more widely available molecular assays for resistance testing will be developed in the future, as has been done for HIV and cytomegalovirus.
        </p>
        <p class="headingAnchor" id="H1909244">
         <span class="h1">
          AVAILABLE AGENTS FOR ACYCLOVIR-RESISTANT HSV INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above,
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         drug resistance infers cross-resistance to
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         and
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         ; there are no other oral therapeutic options to treat HSV. (See
         <a class="local">
          'Mechanisms of drug resistance'
         </a>
         above.)
        </p>
        <p>
         Alternative intravenous and topical options include formulations of
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         and
         <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">
          cidofovir
         </a>
         , which target the viral DNA polymerase enzyme instead of thymidine kinase; continuous high-dose intravenous
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         ; and
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         as discussed below [
         <a href="#rid26">
          26
         </a>
         ]. Although vidarabine has activity against herpes viruses [
         <a href="#rid27">
          27
         </a>
         ], it is not effective in patients with acyclovir resistance, as discussed below.
        </p>
        <p>
         Due to the toxicity of alternative therapies, it is recommended that an infectious disease physician co-manage patients with acyclovir-resistant herpes.
        </p>
        <p class="headingAnchor" id="H28740848">
         <span class="h2">
          Foscarnet
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited clinical data on the use of
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         for acyclovir-resistant HSV infection in persons with HIV infection are available from the early 1990s prior to the availability of potent antiretroviral therapy [
         <a href="#rid17">
          17,28-30
         </a>
         ]; however, foscarnet remains the drug of choice for treatment of acyclovir-resistant herpes due to limited therapeutic options [
         <a href="#rid19">
          19,31
         </a>
         ].
        </p>
        <p>
         In a 1991 clinical trial involving 25 AIDS patients (CD4 &lt;20 cells/mm
         <sup>
          3
         </sup>
         ) with acyclovir-resistant mucocutaneous HSV infection, 14 patients were randomly assigned to antiviral therapy with
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         (40 mg/kg of body weight intravenously every eight hours) or vidarabine (15 mg/kg intravenous daily) [
         <a href="#rid17">
          17
         </a>
         ]. Severe neurologic toxicity was observed in three of six patients who received vidarabine, and as a result the Data Safety Monitoring Board recommended that the trial be stopped. Eleven additional patients were treated with open label foscarnet. All isolates were susceptible to foscarnet and vidarabine in vitro. Therapy was given for 10 days if all lesions had healed, or up to 42 days for patients with a partial response. The median number of lesions per patient was similar in both treatment arms at baseline (n = 2).
        </p>
        <p>
         Lesions in the first eight patients assigned to
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         healed completely after 10 to 24 days of treatment. HSV lesions recurred in 17 of 25 patients within a median of 42 days of resolution [
         <a href="#rid17">
          17
         </a>
         ]. Patients who were retreated with foscarnet had clinical resolution of their recurrent ulcers. Of note, many of these viral isolates had improved in vitro sensitivity to
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         .
        </p>
        <p>
         In contrast to
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         and its related compounds,
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         is associated with significant toxicity. Adverse effects related to foscarnet include renal toxicity and electrolyte abnormalities, such as hypomagnesemia, hypocalcemia and hypokalemia. Patient monitoring is discussed below and elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8288.html" rel="external">
          "Foscarnet: An overview", section on 'Toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28740855">
         <span class="h2">
          Topical therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical therapies have been used with some reported success for
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         ‐resistant HSV genital lesions that are refractory to
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         or in patients that cannot tolerate foscarnet [
         <a href="#rid16">
          16,32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H33539866">
         <span class="h3">
          Cidofovir
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">
          Cidofovir
         </a>
         is a nucleotide analogue with in vitro activity against a broad range of herpesviruses, including thymidine-kinase deficient HSV-1 and HSV-2 isolates [
         <a href="#rid16">
          16
         </a>
         ]. In a double-blind clinical trial, 30 AIDS patients with acyclovir-resistant HSV infection (median of two lesions at baseline) were randomly assigned to topical cidofovir gel or placebo gel for five days [
         <a href="#rid16">
          16
         </a>
         ]. Ten of 20 patients receiving cidofovir attained complete lesion resolution or 50 percent improvement in clinical symptoms compared with none of the patients receiving placebo. The median time for a clinical response to therapy was 21 days. Application site reactions occurred in 25 percent of cidofovir-treated patients and 20 percent of placebo-treated patients.
        </p>
        <p>
         The application of these data to clinical practice is mainly limited by the drug itself; topical
         <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">
          cidofovir
         </a>
         is not commercially available and must be compounded by the pharmacy. Thus, it is difficult to standardize dosing [
         <a href="#rid20">
          20
         </a>
         ]. Information on the use of intravenous cidofovir is found below. (See
         <a class="local">
          'Intravenous cidofovir'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H33539873">
         <span class="h3">
          Other therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Case reports describe the successful use of intralesional
         <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">
          cidofovir
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ] and topical 5%
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         [
         <a href="#rid34">
          34-36
         </a>
         ].
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          Thalidomide
         </a>
         has also been used as a salvage therapy in severe cases of acyclovir-resistant herpes [
         <a href="#rid37">
          37,38
         </a>
         ].
         <sup>
         </sup>
        </p>
        <p class="headingAnchor" id="H28740862">
         <span class="h1">
          MANAGEMENT OF DRUG-RESISTANT ULCERATIVE DISEASE
         </span>
        </p>
        <p class="headingAnchor" id="H33539880">
         <span class="h2">
          Intravenous acyclovir
         </span>
         <span class="headingEndMark">
          —
         </span>
         Upon clinical suspicion of acyclovir-resistant HSV infection in patients receiving oral antiviral therapy, we suggest sending a culture for drug resistance testing and switching to intravenous
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (10 mg/kg IV every 8 hours), which achieves higher serum concentrations than oral acyclovir [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview", section on 'Basic pharmacokinetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1909392">
         <span class="h2">
          Intravenous foscarnet
         </span>
         <span class="headingEndMark">
          —
         </span>
         After the initiation of intravenous
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         , if there is no improvement in lesion size over approximately 5 to 10 days, or if the lesion progresses, the patient should be empirically treated with
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         (40 mg/kg intravenously every eight hours) while awaiting results of drug resistance testing. Foscarnet should be continued for a minimum of three weeks or until healing of all mucocutaneous ulcers.
        </p>
        <p>
         During
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         therapy, patients should receive aggressive pre- and post-hydration to prevent nephrotoxicity and be carefully monitored twice weekly for electrolyte abnormalities, renal dysfunction, and bone marrow suppression. Elevations in creatinine can be seen within one to two weeks of foscarnet initiation. Concomitant nephrotoxic agents should be avoided, whenever possible.
        </p>
        <p class="headingAnchor" id="H33539887">
         <span class="h2">
          Intravenous cidofovir
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, resistance to
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         may occur; intravenous
         <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">
          cidofovir
         </a>
         (5 mg/kg/week) has been used with variable success in these cases, although there are limited data on the efficacy of intravenous cidofovir for the treatment of acyclovir-resistant HSV in the patient with HIV [
         <a href="#rid40">
          40
         </a>
         ] and only scant data are available in other immunocompromised hosts [
         <a href="#rid41">
          41-43
         </a>
         ].
        </p>
        <p>
         Among patients with HIV, intravenous
         <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">
          cidofovir
         </a>
         has been used in patients with HIV and cytomegalovirus retinitis. However, intravenous administration of this drug is associated with severe toxicity, including neutropenia, nausea and vomiting, and nephrotoxicity; coadministration with oral
         <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">
          probenecid
         </a>
         and aggressive intravenous hydration (both pre- and post-dosing of cidofovir) are important adjunctive modalities to decrease the risk of adverse events.
        </p>
        <p class="headingAnchor" id="H1909462">
         <span class="h2">
          Patients with intolerance to foscarnet
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic options for the patient who is intolerant to
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         , or who has severe toxicity on therapy, are limited:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continuous high-dose
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (30 to 45 mg/kg/day) has been successfully utilized for acyclovir-resistant herpes in other immunocompromised patient populations (ie, hematopoietic stem cell transplant recipients) [
         <a href="#rid44">
          44
         </a>
         ]. There are no data on this approach in patients with HIV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Topical therapies (eg,
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         or
         <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">
          cidofovir
         </a>
         ) may also be considered, although topical cidofovir requires compounding by the local pharmacy and, as noted above, the dosing is not standardized.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28740890">
         <span class="h1">
          PATIENT MANAGEMENT AFTER RESOLUTION OF LESIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1235771">
         <span class="h2">
          Antiviral suppression of genital HSV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with recurrent drug-sensitive genital herpes can be usually managed with either chronic maintenance, or “suppressive therapy”, or with treatment of the episodes as they occur, known as “episodic therapy”.
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         , or
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         are all effective for reducing recurrences of HSV genital lesions among patients with drug-sensitive infection, both those with and without HIV. Of note, several of the recommended dosing regimens in the patient with HIV are higher for acyclovir, famciclovir, and valacyclovir compared with the HIV-seronegative patient. (See
         <a class="medical medical_review" href="/z/d/html/16255.html" rel="external">
          "Treatment of genital herpes simplex virus type 2 in people living with HIV", section on 'Treatment strategies for recurrent disease'
         </a>
         .)
        </p>
        <p>
         Unlike in many other infections, daily suppressive therapy with nucleoside analogues reduces, rather than increases, the risk of
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         resistance in immunocompromised patients. This concept was well illustrated in a retrospective study of three consecutive cohorts of hematopoietic stem-cell transplant recipients (n = 2049), which received acyclovir prophylaxis for varying durations of time after transplantation [
         <a href="#rid45">
          45
         </a>
         ]. Cohort 1 received acyclovir for 30 days; cohort 2 received acyclovir for one year and cohort 3 received acyclovir for an extended period (greater than one year). The two-year probability of HSV disease was highest in the one-month prophylaxis group compared with the one-year and extended acyclovir prophylaxis groups (32 percent versus 4 percent and none, respectively). In addition, acyclovir-resistant disease developed in more patients in the one-month prophylaxis group compared with the other acyclovir groups (10 patients versus 2 patients and none, respectively).
        </p>
        <p>
         These data in an immunocompromised patient population suggest that long-term use of suppressive prophylactic
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         may prevent the emergence of drug-resistant HSV disease. This point is critical, because withholding anti-HSV therapy to preserve future therapeutic options is more likely to lead to emergence of resistant virus compared with antiviral suppression of HSV reactivation.
        </p>
        <p>
         In patients who have a history of acyclovir-resistant herpes, future HSV recurrences can be caused by either acyclovir-sensitive or acyclovir-resistant strains [
         <a href="#rid17">
          17
         </a>
         ]. Because the risk of HSV reactivation persists, we suggest that patients with a history of acyclovir-resistant herpes be maintained on daily suppressive antiviral therapy with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         or a related agent. If herpetic ulcers recur, repeat resistance testing is recommended to determine whether acyclovir-resistant HSV persists. Dosing recommendations for suppressive therapy are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16255.html" rel="external">
          "Treatment of genital herpes simplex virus type 2 in people living with HIV", section on 'Suppressive therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1909886">
         <span class="h2">
          Optimization of HIV therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is important to note that the clinical trials of HSV treatment in the patient with acyclovir-resistant herpes infection were performed prior to the era of potent antiretroviral therapy (ART). Review of the patient's ART regimen, drug adherence, and drug-drug interactions is suggested to optimize HIV virologic suppression and CD4+ T-cell counts since the risk of drug-resistant herpes is related to immunosuppression. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">
          "When to initiate antiretroviral therapy in persons with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H994922472">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">
          "Society guideline links: Sexually transmitted infections"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">
          "Society guideline links: Opportunistic infections in adults with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28741555">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genital herpes simplex is a common sexually transmitted viral infection that is found worldwide. Manifestations of HSV infection among immunosuppressed patients may be characterized by genital ulcers that are more frequent, severe, and of longer duration than in immunocompetent patient populations. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The risk of drug resistance to
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         , or related members of the nucleoside analog class, is increased among immunocompromised compared with immunocompetent patients. (See
         <a class="local">
          'Prevalence of drug resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other risk factors for HSV drug resistance include a history of recurrent HSV infection, prior
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         exposure, a history of a non-healing lesion, advanced immunosuppression, and intermittent exposure to or suboptimal dosing of acyclovir. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug resistance should be suspected in patients who do not have any improvement in lesion size after 7 to 14 days of antiviral therapy with oral
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         , or a related agent within this same class of drugs. A viral culture and a phenotypic assay for HSV drug resistance testing should be obtained and the patient should be switched to intravenous acyclovir (10 mg/kg IV every 8 hours). Lesion progression, despite intravenous therapy, would be suggestive of drug resistance. Clinicians should also be certain that the appropriate dosing regimens are being used. (See
         <a class="local">
          'When to suspect HSV-related drug resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We recommend
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         (40 mg/kg intravenously every eight hours) for treatment of suspected or documented drug-resistant HSV-associated ulcerative disease (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Foscarnet should be continued until full lesion resolution. Patients should be carefully monitored for renal toxicity, bone marrow suppression and electrolyte abnormalities twice weekly. (See
         <a class="local">
          'Management of drug-resistant ulcerative disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who have a history of acyclovir-resistant herpes, future HSV recurrences can be related to either acyclovir-sensitive or acyclovir-resistant strains. Daily suppressive therapy with nucleoside analogues reduces, rather than increases, the risk of
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         resistance in immunocompromised patients. (See
         <a class="local">
          'Management of drug-resistant ulcerative disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Because the risk of HSV reactivation persists, we suggest that patients with a history of acyclovir-resistant herpes be maintained on chronic suppressive antiviral therapy with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         or a related agent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Scrutiny of the patient’s antiretroviral therapy regimen, drug adherence, and drug-drug interactions is suggested to optimize CD4+ T-cell counts since the risk of drug-resistant herpes is related to immunosuppression. (See
         <a class="local">
          'Patient management after resolution of lesions'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370:2127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992; 327:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004; 39 Suppl 5:S248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christophers J, Clayton J, Craske J, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998; 42:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schalkwijk HH, Snoeck R, Andrei G. Acyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives. Biochem Pharmacol 2022; 206:115322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 2002; 186 Suppl 1:S40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stránská R, Schuurman R, Nienhuis E, et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 2005; 32:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehrman SN, Douglas JM, Corey L, Barry DW. Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity. Ann Intern Med 1986; 104:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins P, Ellis MN. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. J Med Virol 1993; Suppl 1:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kriesel JD, Spruance SL, Prichard M, et al. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis 2005; 192:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seang S, Boutolleau D, Burrel S, et al. Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection. Int J STD AIDS 2014; 25:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997; 176:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991; 325:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cury K, Valin N, Gozlan J, et al. Bipolar hypertrophic herpes: an unusual presentation of acyclovir-resistant herpes simplex type 2 in a HIV-infected patient. Sex Transm Dis 2010; 37:126.
          </a>
         </li>
         <li class="breakAll">
          Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on December 01, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lingappa JR, Celum C. Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection. Drugs 2007; 67:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta R, Wald A. Genital herpes: antiviral therapy for symptom relief and prevention of transmission. Expert Opin Pharmacother 2006; 7:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safrin S, Elbeik T, Phan L, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1994; 38:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burrel S, Deback C, Agut H, Boutolleau D. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010; 54:4833.
          </a>
         </li>
         <li class="breakAll">
          University of Washington Laboratory Test Guide. HSV Acyclovir Drug Resistance by Sanger Sequencing. https://testguide.labmed.uw.edu/public/view/HSVDR (Accessed on January 13, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson-Jones D, Wald A, Celum C, et al. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials. J Clin Microbiol 2010; 48:3496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am J Med 1992; 92:3S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitley RJ, Gnann JW Jr, Hinthorn D, et al. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J Infect Dis 1992; 165:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardy WD. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. Am J Med 1992; 92:30S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990; 161:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989; 320:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lateef F, Don PC, Kaufmann M, et al. Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS. Arch Dermatol 1998; 134:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castelo-Soccio L, Bernardin R, Stern J, et al. Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir. Arch Dermatol 2010; 146:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez V, Molina JM, Scieux C, et al. Topical imiquimod for recurrent acyclovir-resistant HSV infection. Am J Med 2006; 119:e9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbo L, Vincek V, Dickinson G, et al. Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod. Clin Infect Dis 2007; 44:e25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danielsen AG, Petersen CS, Iversen J. Chronic erosive herpes simplex virus infection of the penis in a human immunodeficiency virus-positive man, treated with imiquimod and famciclovir. Br J Dermatol 2002; 147:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes A, McMenamin M, Mulcahy F, Bergin C. Thalidomide therapy for the treatment of hypertrophic herpes simplex virus-related genitalis in HIV-infected individuals. Clin Infect Dis 2007; 44:e96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verberkmoes A, Boer K, Wertheim PM, et al. Thalidomide for genital ulcer in HIV-positive woman. Lancet 1996; 347:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lalezari JP, Drew WL, Glutzer E, et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 1994; 170:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000; 31:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrei G, Fiten P, Goubau P, et al. Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient. Transpl Infect Dis 2007; 9:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LoPresti AE, Levine JF, Munk GB, et al. Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. Clin Infect Dis 1998; 26:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JH, Schaenman JM, Ho DY, Brown JM. Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients. Biol Blood Marrow Transplant 2011; 17:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erard V, Wald A, Corey L, et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 196:266.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16701 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18156035" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Genital herpes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1288525" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Acyclovir: a decade later.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1416838" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Resistance of herpesviruses to antiviral drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15494896" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2536136" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9559798" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Survey of resistance of herpes simplex virus to acyclovir in northwest England.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36309081" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Acyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12353186" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12523920" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15572000" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14715760" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3010782" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8245894" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15942905" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Recurrent antiviral-resistant genital herpes in an immunocompetent patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24535691" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9333146" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1649971" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19858782" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Bipolar hypertrophic herpes: an unusual presentation of acyclovir-resistant herpes simplex type 2 in a HIV-infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19858782" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Bipolar hypertrophic herpes: an unusual presentation of acyclovir-resistant herpes simplex type 2 in a HIV-infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17284082" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16556084" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Genital herpes: antiviral therapy for symptom relief and prevention of transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8092821" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733037" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733037" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20702659" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1371038" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mechanism of action of foscarnet against viral polymerases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1538151" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1531285" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2161035" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2536137" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19747629" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9762047" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20157021" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16651045" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Topical imiquimod for recurrent acyclovir-resistant HSV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17205432" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12410731" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Chronic erosive herpes simplex virus infection of the penis in a human immunodeficiency virus-positive man, treated with imiquimod and famciclovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17479932" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Thalidomide therapy for the treatment of hypertrophic herpes simplex virus-related genitalis in HIV-infected individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8598789" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Thalidomide for genital ulcer in HIV-positive woman.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21078929" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8077713" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11049772" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17461998" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9502489" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20615475" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17570114" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
